Idorsia AG WKN A2DTEB | ISIN CH0363463438 | Aktie Watchlist Musterdepot Alert Factsheet 08.05.24 19:11 Bid: - | Ask: - 2,3000 USD - (-) Nasdaq Other OTC SIX Swiss Exchange Nasdaq Other OTC Baader Bank (Baadex) Lang & Schwarz Berlin EUREX gettex Hamburg München Verkaufen Kaufen Übersicht Chart-Pro Analysen Nachrichten Kurse & Handelsplätze Letzte Umsätze 14.05.24 GNW-Adhoc: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call 06.05.24 GNW-Adhoc: Bondholders approve amended terms of the 2024 convertible bonds 01.05.24 GNW-Adhoc: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond 26.04.24 GNW-Adhoc: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension 23.04.24 GNW-Adhoc: Idorsia publishes an invitation to a bondholder meeting 17.04.24 GNW-Adhoc: Idorsia publishes a Financial Status required for an upcoming bondholder meeting 11.04.24 GNW-Adhoc: Idorsia takes steps to address short-term liquidity needs 22.03.24 GNW-Adhoc: Idorsia thanks Guy Braunstein for his years of service as he retires 20.03.24 ROUNDUP/Aktien Europa Schluss: Moderate Verluste vor US-Zinsentscheid 20.03.24 Aktien Europa: Verluste vor US-Zinsentscheid - Kering belastet Luxusgüterbranche 20.03.24 GNW-Adhoc: US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives 18.03.24 GNW-Adhoc: Idorsia and Viatris successfully close the transaction for the global research and development collaboration 28.02.24 GNW-Adhoc: Idorsia and Viatris enter into a significant global research and development collaboration 28.02.24 Idorsia and Viatris enter into a significant global research and development collaboration 10.01.24 GNW-Adhoc: Idorsia presents at the J.P. Morgan Healthcare Conference - Adapting Idorsia for sustainable value creation